Click here to close Hello! We notice that you are using Internet Explorer, which is not supported by Xenbase and may cause the site to display incorrectly. We suggest using a current version of Chrome, FireFox, or Safari.
XB-IMG-152394

Xenbase Image ID: 152394


Supplementary material Supplementary Fig. 2 Lef1-GR and Tcf3-VP16-GR activate canonical Wnt signaling in earlyXenopusembryos as indicated by secondary axis induction. A Schematic representation of wild type and modified GR-fusion constructs of Tcf3A and Lef1 employed for stimulation of canonical Wnt signaling. Tcf3-VP16-GR is a construct, where the β-catenin binding domain was replaced with the VP16 transcriptional activator ( Vonica et al., 2000, Agathocleous et al., 2009 and Borday et al., 2012). B Experimental set up: embryos were injected with the respective constructs in one ventral blastomeres at the 4-cell stage, treated with Dexamethasone at the 16-cell stage, and secondary axes were scored at early tailbud stage 28. C Graph summarizing the percentage of secondary axes of 3 independent experiments of embryos injected with 50 pg of Tcf3-VP16-GR RNA. Numbers of injected embryos and standard error of the means are indicated for each column. Ventral injection of 50 pg Tcf3-VP16-GR RNA caused on average 79% of double axes and this effect was not observed in the absence of Dexamethasone treatment. In general the effects of this construct were weaker compared to Lef1-GR or BIO-treatment, and this is also reflected in its ability to cause NC migration defects (Supplementary Fig. 4). D Graph summarizing the percentage of secondary axis in 3 independent experiments after injection of increasing concentrations of the Lef1-GR construct. RNA concentrations of 25, 50 or 75 pg resulted in more than 80% of embryos with double axes and this effect was not observed in embryos that were injected with the respective RNAs, but not treated with Dexamethasone.

Image published in: Maj E et al. (2016)

Copyright © 2016. Image reproduced with permission of the Publisher, Elsevier B. V.

Larger Image
Printer Friendly View

Return to previous page